Top 10 Pharma CEO salaries of 2010

By Liz Hollis and Erica Teichert

Welcome to our annual look at the biggest CEO in the pharma industry. Despite a year fraught with manufacturing issues and drug recalls, Johnson & Johnson CEO Bill Weldon takes the top spot, with $28.7 million in 2010 pay. And Novartis' Daniel Vasella grabs the No. 2 spot thanks to a lucrative golden handshake.

Next year we'll have to say goodbye to a few familiar faces that are making their final appearance on this list. Pfizer's Jeff Kindler won't be back next year, nor will Vasella or Richard Clark of Merck. All of these CEOs will be replaced by new executives that will appear on the list. For example, Ian Read, Pfizer's new CEO, earned more than $17 million last year, even though he didn't become CEO until Dec. 5. George Scangos, formerly of Exelixis and now Biogen Idec CEO, was paid $9.4 million last year--and he didn't come on board until more than halfway through the year.

Others are waiting, too. Allergan's David Pyott ($12.7 million), Bristol-Myers Squibb's Lamberto Andreotti ($11.8 million) and Baxter's Robert Parkinson ($11.5 million) were close to making the list. Click below to get all the details on the top 10 highest paid biotech and pharma CEOs of 2010.

1. Bill Weldon - J&J - $28.7M

2. Daniel Vasella - Novartis - $27M

3. Miles White - Abbott-  $25.6M

4. Jeffrey Kindler - Pfizer-  $24.7M

5. Richard Clark - Merck - $24.6M

6. Robert Coury - Mylan - $22.9M

7. Kevin Sharer - Amgen - $21.1M

8. James Mullen - Biogen Idec - $20M

9. John Lechleiter - Eli Lilly - $16.5M

10. John Martin - Gilead Sciences - $14.2M


Suggested Articles

Oklahoma politicians contend J&J should be on the line for future abatement costs even after a $572 million verdict, but J&J sees things differently.

Abbott helmsman Miles White, who oversaw the spinoffs of AbbVie and Hospira, will step down as CEO after 21 years at the top job.

Mylan is the most recent drugmaker facing the FDA's ire over a tainted API that led to a global recall of "sartan"-based drugs last year.